bluebird bio, California Institute for Regenerative Medicine hematology news

CIRM awarded $9.3 million to bluebird bio under CIRM's Strategic Partnership Awards Initiative. The funds will be used to support a U.S. Phase I/II trial of LentiGlobin gene therapy to treat beta thalassemia, which is expected to begin next year. The lentiviral vector encoding the human beta globin gene delivered into a patient's own hematopoietic stem cells in the bone marrow is already in a European Phase I/II trial to treat beta thalassemia and sickle cell disease. ...